Learn about Tessellate BIO and meet the team
About us
Tessellate BIO was founded to develop precision oncology approaches to treat cancers with high unmet need.
We are initially focusing on validated targets to address the group of cancers that depend on the alternative lengthening of telomeres (ALT) which can be detected with our proprietary companion diagnostic.
We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response pathways and loss-of-function of tumor suppressors.
Tessellate BIO’s values are based on international collaborations and unifying approaches. Inspired by the tessellating works of M.C. Escher, we designed this image to represent our therapy’s journey from chromosome to patient.
and meet the team.
Click on the images
to know more
Meet the team
Tessellate BIO was founded based on the research of two renowned scientists in the field of telomere biology, Professors Hilda Pickett and Claus Azzalin.
We have a driven multinational team of industry- and biotech-experienced R&D leaders and scientists.
The Tessellate BIO team is supported by a scientific advisory board of internationally recognized leaders in cancer research, synthetic lethality, DNA damage response, alternative lengthening of telomeres, clinical development of precision medicines, and a board of directors experienced in the management of early-stage life science companies.
Leadership Team
Andree Blaukat
CEO
Jürgen Moll
CSO
Katie Chapman
Head of Discovery Biology
Laurent Rigoreau
Head of Medicinal Chemistry
Joris Schuurmans
Head of Diagnostics
Asiya Giniatullina
Head of Operations
Lee Larcombe
Head of Bioinformatics
Andrew Lightfoot
Advisor
Board of Directors
Eliot Forster
Chair of the Board
Claus Azzalin
Co-Founder
Andree Blaukat
CEO
Daniela Couto
BioGeneration Ventures
Rogier Rooswinkel
Forbion
Keno Gutierrez
BioGeneration Ventures
Founders
Professor Hilda Pickett
Professor Claus Azzalin
Leadership Team
Andree Blaukat
CEO
Jürgen Moll
CSO
Katie Chapman
Head of Discovery Biology
Laurent Rigoreau
Head of Medicinal Chemistry
Joris Schuurmans
Head of Diagnostics
Asiya Giniatullina
Head of Operations
Lee Larcombe
Head of Bioinformatics
Andrew Lightfoot
Advisor
Board of Directors
Eliot Forster
Chair of the Board
Claus Azzalin
Co-Founder
Andree Blaukat
CEO
Daniela Couto
BioGeneration Ventures
Rogier Rooswinkel
Forbion
Keno Gutierrez
BioGeneration Ventures
Scientific Advisory Board
Professor Roger Reddel
Chair
Professor Hilda Pickett
Co-Founder
Professor Claus Azzalin
Co-Founder
Professor Christopher Lord
Professor René Bernards
Professor Andrew Deans
Professor George Demetri
Professor Giulio Draetta
Professor Timothy Yap
Professor Sandra Strauss
Leadership Team
Andree Blaukat
CEO
Jürgen Moll
CSO
Katie Chapman
Head of Discovery Biology
Laurent Rigoreau
Head of Medicinal Chemistry
Joris Schuurmans
Head of Diagnostics
Asiya Giniatullina
Head of Operations
Lee Larcombe
Head of Bioinformatics
Andrew Lightfoot
Advisor
Board of Directors
Eliot Forster
Chair of the Board
Claus Azzalin
Co-Founder
Andree Blaukat
CEO
Daniela Couto
BioGeneration Ventures
Rogier Rooswinkel
Forbion
Keno Gutierrez
BioGeneration Ventures
Scientific Advisory Board
Professor Roger Reddel
Chair
Professor Hilda Pickett
Co-Founder
Professor Claus Azzalin
Co-Founder
Professor Christopher Lord
Professor René Bernards
Professor Andrew Deans
Professor George Demetri
Professor Giulio Draetta
Professor Timothy Yap
Professor Sandra Strauss
Founders
Professor Hilda Pickett
Professor Claus Azzalin
Investors
Would you like to know more?
Privacy Policy – Terms & Conditions – Cookie policy